Lineage Cell Therapeutics (LCTX) Research & Development (2010 - 2026)

Lineage Cell Therapeutics' Research & Development history runs 17 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• On a quarterly basis, Research & Development rose 35.97% year-over-year to $4.2 million in Q1 2026; TTM through Mar 2026 was $18.8 million, a 49.88% increase from a year earlier, with the FY2025 full-year figure at $17.7 million, up 42.15% from the prior year.
• Research & Development declined to $4.2 million in Q1 2026 per LCTX's latest filing, from $8.2 million in the prior quarter.
• Across five years, Research & Development topped out at $8.2 million in Q4 2025 and bottomed at $2.9 million in Q2 2024.
• The 5-year median for Research & Development is $3.4 million (2024), against an average of $3.8 million.
• Across the five-year window, Research & Development plunged 83.44% in 2022 and surged 140.67% in 2025, its largest moves.
• Year by year, Research & Development stood at $4.1 million in 2022, then decreased by 4.82% to $3.9 million in 2023, then retreated by 12.37% to $3.4 million in 2024, then jumped by 140.67% to $8.2 million in 2025, then sank by 48.6% to $4.2 million in 2026.
• Per Business Quant, the three latest LCTX Research & Development figures stand at $4.2 million (Q1 2026), $8.2 million (Q4 2025), and $3.3 million (Q3 2025).